Compounds that Activate KCNQ(2-5) Family of Potassium Ion Channels

Voltage-Gated Ion Channels as Drug Targets

Volumn 29, Issue , 2006, Pages 355-380

  McNaughton Smith, Grant ^a   Wickenden, Alan D ^a  

^a NONE

Author keywords

Compounds that activate KCNQ(2 5) family of potassium ion channels; Potassium channels

Indexed keywords

KINETIC THEORY;

POTASSIUM CHANNELS; POTASSIUM ION CHANNELS;

POTASSIUM COMPOUNDS;

EID: 85018213687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608141.ch7f     Document Type: Chapter

References (62)

1. Gutman, G.A, et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol. Rev. 2003, 55(4), 583-586.
2. Jentsch, T.J. Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. Neurosci. 2000, 1, 20-30.
3. Gribkoff, V.K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets 2003, 7(6), 737-748.
4. Cooper, E.C. Harrington, E., Jan, Y.N., Jan, L.Y. M-channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J. Neurosci. 2001, 21, 9529-9540.
5. Wang, H-S., Pan, Z., Shi, W., Brown, B. S., Wymore, R.S., Cohen, U.S., Dixon, J.E., McKinnon, D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science, 1998, 282, 1890-1893.
6. + current in a vertebrate neuron. Nature, 1980, 283, 673-676.
7. Wickenden, A.D, Roeloffs, R., McNaughton-Smith, G.A., Rigdon, G.C. Expert Opin. Ther. Patents 2004, 14(4), 457-469.
8. Seaman, C.A., Sheridan, P.H., Engel, J., Molliere, M., Narang, P.K., Nice, F.J. Flupirtine. pp. 135-146. In New Anticonvulsant Drugs, Meldrum, B.S., Porter R.J. (eds), Libbey, London, 1985.
9. Seydel, J.K., Schaper, K-J., Coates, E.A., Cordes, H.P., Emig, P., Engel, J., Kutscher, B., Polymeropoulos, E.E. Synthesis and quantitative structure-activity relationship ofanticonvulsant 2,3,6-triaminopyridines. J. Med. Chem. 1994, 37, 3016-3022.
10. Rocstock, A. Tober, C., Rundfeldt, C., Bartsch, R., Engel, J., Polymeropoulos, E. E, Kutscher, B., Löscher, W., Hönack, D., White, H.S., Wolf, H.H. D-23129: a new anticonvulsant with broad-spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996, 23, 211-223.
11. Kapetanovic, I.M., Rundfeldt, C. D-23129: a new anticonvulsant compound. CNS Drug Rev. 1996, 2, 308-321.
12. Rundfeldt, C. Armand, V., Heinemann, U. Multiple actions of the new anticonvulsant D-23129 on voltage-gated inward currents and GABA-induced currents in cultured neuronal cells (abstract). Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 351(suppl), R160.
13. Kapetanovic, I.M. Yonekawa, WD. Kupferberg, H.J. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vivo. Epilepsy Res. 1995, 22, 167-173.
14. + channels in neuronal cells. Eur. J. Pharmacol. 1997, 336, 243-249.
15. + channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res. 1999, 35, 99-107.
16. Wickenden, A.D., Yu, W., Zou, A., Jegla, T., Wagoner, P.K. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000, 58, 591-600.
17. Tatulian, L., Delmas, P., Abogadie, F.C., Brown, D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 2001, 21(15), 5535-5545.
18. Jentsch, T. J. Neuronal KCNQ potassium channels: Physiology and role in disease. Nat. Rev. Neurosci. 2000, 1, 21-30.
19. Rundfeldt, C., Netzer, R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett. 2000, 282, 73-76.
20. Wickenden, A.D., Zou, A., Wagoner, P.K, Jegla, T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br. J. Pharmacol. 2001, 132, 381-384.
21. Ilyin, VI., Carlin, K.P., Hodges, D.D., Robledo, S, Woodward, R.M. Flupritine a positive modulator of heteromeric KCNQ2/Q3 channels. Soc. Neurosci. Abstr. 2002, 758.10.
22. H. Lundbeck A/S. 1,2,4-Triaminobenzene derivatives useful for the treating disorders of the central nervous system. WO 04058739.
23. H. Lundbeck A/S. Substituted indoline and indole derivatives. WO04096767.
24. Nikel, B., Shandara, A.A., Godlevsky, L.S., Mazarati, A.M., Kupferberg, H.J, Szelenyi, I. Anticonvulsant activity of a new drug D-20443 (abstract). Epilepsia, 1993b, 34(suppl), S95.
25. Dailey, J.W., Cheong, J.H., Ko, K.H., Adams-Curtis, L.E, Jobe, P.C. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci. Lett. 1995, 195, 77-80.
26. Tober, C., Rocstock, A., Rundfeldt, C., Bartsch, R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 1996, 303, 163-169.
27. Porter A.J. et al. Effect of flupirtine on uncontrolled partial or absence seizures. Epilepsia, 1983, 24, 253-254.
28. Blackburn-Munro, G., Jensen, B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharamcol. 2003, 460, 109-116.
29. Dost, R., Rocstock, A., Rundfeldt, C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ channel activation. Naunyn-Schmiedebergs Arch. Pharmacol. 2004, 369, 382-390.
30. Passmore, G.M., Selyanko, A.A., Mistry M. et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci., 2003, 23, 7227-7236.
31. Carlsson, K.H., Jurna, I. Depression by flupirtine, a novel analgesic, of motor and sensory responses of the nociceptive system in rat spinal cord. Eur. J. Pharamcol 1987, 143, 89-99.
32. Bialer, M., Johannessen, S.I. Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002, 51, 31-71.
33. Bialer, M., Johannessen, S.I. Kupferberg, H. J., Levy, R.H., Loiseau, P., Perucca, E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001, 43, 11-58.
34. Porter, A.J., Gratz, E., Narang, P.K. et al. Effect of flupirtine on uncontrolled partial or absence seizures. Epilepsia, 1983, 24, 253-254.
35. Sheridan, P.H., Seaman, C.A., Narang, P.K. et al. Pilot study of flupirtine in refractory seizures. Neurology, (abstract), 1986, 36(suppl), 85.
36. Benzanilides as potassium channel openers. US 6372767 (filed August 4, 1999).
37. Pyridine substituted benzanilides as potassium channel openers. US 6495550 (filed August 4, 1999).
38. Pyrimidines as novel openers of potassium ion channels. WO 03068767 (filed February 14, 2002).
39. Bisarylamines as potassium channel openers. US 6593349 (filed March 19, 2001).
40. nd, 2003.
41. Schrøder, R. L., Jespersen, T., Christophersen, P., Strobaek, D., Jensen, B. S., Olesen, S. P., KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology, 2001, 40, 888-898.
42. Neurosearch A/S. Use of 3-oxindole derivatives as KCNQ potassium channel modulators. WO 02000217.
43. Gribkoff, VK. et al. Nat. Med., 2001, 7 (4), 471-477.
44. Dupuis, D.S., Schrøder, R.L., Jespersen, T., Christensen, J.K., Christophersen, P., Jensen, B.S., Olesen, S.P. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. J. Pharamcol. 2002, 437, 129-137.
45. Bristol-Myers Squibb Company. Fluoro-oxindole derivatives as modulators of KCNQ potassium channels. US 6469042.
46. Hewawasam, P. et al. The synthesis and structure-activity relationship of 3-amino-4-benzylquinolin-2-ones: discovery of novel KCNQ2 channel openers. Bioorg. Med. Chem. Lett. 2004, 14, 1615-1618.
47. Bristol-Myers Squibb Company. 2,4-Disubstituted pyrimidine-5-carboxamides as KCNQ potassium channel modulators. WO 02066036.
48. Bristol-Myers Squibb Company. Cinna-mides as KCNQ potassium channel modulators. WO 02096858.
49. Bristol-Myers Squibb Company. 1-Aryl-2-hydroxethyl amides as potassium channel openers. WO 04047743.
50. Bristol-Myers Squibb Company. 3-Heterocyclic benzylamide derivatives as potassium channel openers. WO 04047744.
51. L'Heureux, A. et al., (S,E)-N-[1-(3-Heteroarylphenyl)ethyl-3-(2-fluorophenyl)-acrylamides: synthesis and KCNQ2 potassium channel opener activity. Bioorg. Med. Chem. Lett. 2005, 15, 363-366.
52. Bristol-Myers Squibb Company. 3-(Pyridyl-piperazin-1-yl)-phenethyl amides as potassium channel openers. WO 04047745.
53. Bristol-Myers Squibb Company. Arylcyclopropylcarboxylic amides as potassium channel openers. WO 04047738.
54. Wu, Y-J. et al. (S)-N-[1-(3-Morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: An orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J. Med. Chem. 2003, 46, 3197-3200.
55. Wu, Y-J. et al. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J. Med. Chem. 2003, 46, 3778-3781.
56. Wu, Y-J., He, H., Sun, L.Q., L'Heureux, A., Chen, J., Dextraze, P., Starrett, J.E., Boissard, C.G., Gribkoff, VK., Natale, J., Dworetzky, S.I. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers. J. Med. Chem. 2004, 47, 2887-2896.
57. Bristol-Myers Squibb Company. 2-Aryl thiazole derivatives KCNQ modulators. WO 04060281.
58. Bristol-Myers Squibb Company. Aminoalkyl thiazole derivatives KCNQ modulators. US 2004/0138268.
59. th, 2003.
60. ICAGEN, Inc. Quinazolinones as potassium channel modulators. WO 04058704.
61. Neurosearch A/S. Novel KCNQ channel modulating compounds and their use. WO 04080377.
62. Ramot at Tel Aviv University Ltd. Derivatives of N-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators. WO 04035037.